Equities research analysts predict that ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) will post ($0.12) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for ZIOPHARM Oncology’s earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.07). ZIOPHARM Oncology posted earnings per share of ($0.13) in the same quarter last year, which would suggest a positive year-over-year growth rate of 7.7%. The company is expected to report its next earnings report on Monday, November 5th.

According to Zacks, analysts expect that ZIOPHARM Oncology will report full year earnings of ($0.50) per share for the current fiscal year, with EPS estimates ranging from ($0.55) to ($0.42). For the next financial year, analysts forecast that the business will report earnings of ($0.37) per share, with EPS estimates ranging from ($0.50) to ($0.22). Zacks’ earnings per share calculations are an average based on a survey of analysts that that provide coverage for ZIOPHARM Oncology.

ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.12).

Several brokerages have weighed in on ZIOP. BidaskClub upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. ValuEngine upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Zacks Investment Research downgraded shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, May 16th. HC Wainwright restated a “buy” rating and issued a $5.50 target price on shares of ZIOPHARM Oncology in a research note on Monday, May 14th. Finally, JPMorgan Chase & Co. downgraded shares of ZIOPHARM Oncology from a “neutral” rating to an “underweight” rating in a research note on Monday, June 18th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company. ZIOPHARM Oncology presently has an average rating of “Hold” and an average target price of $5.25.

ZIOP stock traded up $0.04 during trading on Monday, hitting $2.70. 526,100 shares of the company’s stock traded hands, compared to its average volume of 1,386,920. The firm has a market cap of $378.73 million, a price-to-earnings ratio of -5.09 and a beta of 1.39. ZIOPHARM Oncology has a 1 year low of $2.23 and a 1 year high of $6.60.

A number of institutional investors and hedge funds have recently made changes to their positions in ZIOP. Deutsche Bank AG boosted its stake in ZIOPHARM Oncology by 141.1% in the fourth quarter. Deutsche Bank AG now owns 294,287 shares of the biotechnology company’s stock valued at $1,216,000 after acquiring an additional 172,227 shares in the last quarter. Wells Fargo & Company MN boosted its stake in ZIOPHARM Oncology by 25.8% in the first quarter. Wells Fargo & Company MN now owns 251,068 shares of the biotechnology company’s stock valued at $985,000 after acquiring an additional 51,499 shares in the last quarter. Mackay Shields LLC acquired a new stake in ZIOPHARM Oncology in the first quarter valued at approximately $359,000. Schwab Charles Investment Management Inc. boosted its stake in ZIOPHARM Oncology by 3.0% in the first quarter. Schwab Charles Investment Management Inc. now owns 664,222 shares of the biotechnology company’s stock valued at $2,604,000 after acquiring an additional 19,580 shares in the last quarter. Finally, Private Advisor Group LLC acquired a new stake in ZIOPHARM Oncology in the first quarter valued at approximately $351,000. Institutional investors own 39.30% of the company’s stock.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

Recommended Story: Trading Strategy

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.